Inhibition of cell growth and apoptosis in CaSki, cervical cancer cell line by arsenic compounds.
10.5468/kjog.2010.53.7.616
- Author:
Jung Mi BYUN
1
;
Dae Hoon JEONG
;
Dae Sim LEE
;
Joo Ran KIM
;
Young Nam KIM
;
Eun Jeong JEONG
;
Moon Su SUNG
;
Kyoung Bok LEE
;
Ki Tae KIM
Author Information
1. Department of Obstetrics and Gynecology, Inje University College of Medicine, Busan Paik Hospital, Busan, Korea. buzzmi@chol.com
- Publication Type:Original Article
- Keywords:
Cervical cancer;
Paclitaxel;
Cisplatin;
Arsenic trioxide;
Tetraarsenic oxide;
Apoptosis
- MeSH:
Apoptosis;
Arsenic;
Arsenicals;
Cell Line;
Cisplatin;
Flow Cytometry;
Humans;
Oxides;
Paclitaxel;
Tetrazolium Salts;
Uterine Cervical Neoplasms
- From:Korean Journal of Obstetrics and Gynecology
2010;53(7):616-625
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: To compare inhibition of cell growth and apoptosis in human cervical cancer cell lines (CaSki) by paclitaxel, cisplatin, arsenic trioxide and tetraarsenic oxide. METHODS: Inhibition of cell growth was determined by the water-soluble tetrazolium salts (WSTs) -1 assay. For apoptosis analysis in CaSki cell line treated with single or combination of two agents, CaSki cell line treated with each agent was stained with annexin-V/PI and flow cytometry was performed. RESULTS: Progression of apoptosis in CaSki cell line treated with paclitaxel, cisplatin, arsenic trioxide, and tetraarsenic oxide was time dependent. Inhibition of cell growth in CaSki cell line by paclitaxel, cisplatin, arsenic trioxide, and tetraarsenic oxide was dose and time dependent. Especially, tetraarsenic oxide was more effective in inhibition of CaSki cell growth compared to arsenic trioxide. Group treated with combination of cisplatin and tetraarsenic oxide showed more progressive apoptosis compared to other combination group. CONCLUSION: Tetraarsenic oxide has more potent anti-tumor effects than other agents on CaSki cell line. We need to consider further study about antitumor effect of tetraarsenic oxide through clinical study.
